Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by CMHarring218431on Dec 07, 2023 12:48pm
362 Views
Post# 35773316

Question

QuestionWhy did management decide to put out this PR? Based upon market reaction, it seems most view this as a fluff PR. To the lay person, like myself, it seemed like a nice little news release with a lot of positive info. Apparently, to the knowledgeable, it was not new news but a long winded detailed analysis again of what is possible. Not put out to educate those in the scientific arena, nor any potential suitors. So, I guess it was meant for the masses just to give support to the stock price. Bigger news has been expected and is this all we get until next year??? Again, if any kind of deal is forthcoming...why this release? Could it be that the PR was put out there to entice any big Pharma that wasn't paying close attention. Just random thoughts. IMHO
<< Previous
Bullboard Posts
Next >>